Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.|Institute of Molecular Oncology, Showa University, Tokyo, Japan.
Yasutsuna
Y
Sasaki
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Kazuyuki
K
Hamada
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Toshikado
T
Kaneta
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Takehiro
T
Takahashi
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Yutaro
Y
Kubota
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Hiroo
H
Ishida
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Wataru
W
Ichikawa
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*